Cogent Biosciences COGT 深 沪
等待开盘 10-22 09:30:00 美东时间
31.43
+0.190
+0.61%
华盛通- 最 高31.94
- 今 开31.26
- 成交量 209.98万股
- 最 低 31.20
- 昨 收 31.24
- 总市值 54.54亿
- 52周最高 43.73
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 13.78
- 委 比 23.89%
- 总股本 1.74亿
- 历史最高 43.73
- 量 比 0.81
- 振 幅 2.37%
- 历史最低 3.67
- 每 手 1
- 风险率 5.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a market capitalization of $5.21 billion. Buying $1000 In COGT: If an investor had bought $1000 of COGT ...
今天 00:45
$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalization of $5.38 billion. Buying $1000 In COGT: If an investor had bought $1000 of COGT ...
10-03 05:48
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
09-15 21:54
Cogent Bio granted third FDA review for lead asset
Cogent Biosciences (COGT) on Tuesday announced that the FDA has accepted its marketing application for its lead candidate, bezuclastinib, for a rare form of blood cancer, marking the third indication ...
09-15 20:28
Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal
The latest announcement is out from Cogent Biosciences ( ($COGT) ). On Septembe...
09-03 06:14
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a market capitalization of $6.12 billion. Buying $100 In COGT: If an investor had bought $100 of COGT st...
09-01 06:30
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
08-18 00:08
